LBL-042

N/A

Report date: 2025/02/12 18:02:36

Base Information

Drug NameLBL-042
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor B1 inhibitorsanti-Leukocyte immunoglobulin-like receptor subfamily B member 2Anti-PD-1
TargetsLeukocyte immunoglobulin-like receptor B1Leukocyte immunoglobulin-like receptor subfamily B member 2Programmed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A